b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30194661</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>11</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>11</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1179-1950</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>78</Volume>\n                    <Issue>14</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Sep</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Drugs</Title>\n                <ISOAbbreviation>Drugs</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Elagolix: First Global Approval.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1501-1508</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-018-0977-4</ELocationID>\n            <Abstract>\n                <AbstractText>Elagolix (ORILISSA\xe2\x84\xa2), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women. In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain associated with endometriosis. This approval was based on positive results in two replicate phase III trials; additional phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication. Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clinical development for heavy menstrual bleeding associated with uterine fibroids in the aforementioned locations. This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain associated with endometriosis.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Lamb</LastName>\n                    <ForeName>Yvette N</ForeName>\n                    <Initials>YN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>New Zealand</Country>\n            <MedlineTA>Drugs</MedlineTA>\n            <NlmUniqueID>7600076</NlmUniqueID>\n            <ISSNLinking>0012-6667</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006727">Hormone Antagonists</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011966">Receptors, LHRH</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>5B2546MB5Z</RegistryNumber>\n                <NameOfSubstance UI="C539351">elagolix</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="ErratumIn">\n                <RefSource>Drugs. 2018 Nov 15;:</RefSource>\n                <PMID Version="1">30430369</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006727" MajorTopicYN="N">Hormone Antagonists</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006845" MajorTopicYN="N">Hydrocarbons, Fluorinated</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011966" MajorTopicYN="N">Receptors, LHRH</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>9</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>9</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30194661</ArticleId>\n            <ArticleId IdType="doi">10.1007/s40265-018-0977-4</ArticleId>\n            <ArticleId IdType="pii">10.1007/s40265-018-0977-4</ArticleId>\n            <ArticleId IdType="pmc">PMC6244606</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Reprod Sci. 2014 Mar;21(3):363-71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23885105</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Obstet Gynecol. 2018 Jul;132(1):147-160</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29889764</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Reprod Sci. 2014 Nov;21(11):1341-51</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25249568</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Endocrinol Metab. 2009 Feb;94(2):545-51</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19033369</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Pharmacokinet. 2018 Oct;57(10):1295-1306</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29476499</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Fertil Steril. 2017 Jul;108(1):152-160.e4</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28579415</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Endocrinol Metab. 2017 May 1;102(5):1683-1691</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28323948</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2017 Jul 6;377(1):28-40</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28525302</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Endometr Pelvic Pain Disord. 2013 Jul;5(3):105-115</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30320043</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'